Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Corneal Neovascularization D016510 8 associated lipids
Xeroderma Pigmentosum D014983 6 associated lipids
Shock, Cardiogenic D012770 5 associated lipids
Hypertrophy, Right Ventricular D017380 4 associated lipids
Strongylida Infections D017206 5 associated lipids
Enterocolitis, Necrotizing D020345 3 associated lipids
Milk Hypersensitivity D016269 4 associated lipids
Hematoma, Subdural D006408 3 associated lipids
Venous Thrombosis D020246 11 associated lipids
Blood Loss, Surgical D016063 6 associated lipids
Purpura, Thrombotic Thrombocytopenic D011697 6 associated lipids
Platelet Storage Pool Deficiency D010981 3 associated lipids
Thrombophilia D019851 6 associated lipids
Hepatitis B, Chronic D019694 4 associated lipids
Respiratory Syncytial Virus Infections D018357 10 associated lipids
Dementia, Multi-Infarct D015161 2 associated lipids
Leukocyte-Adhesion Deficiency Syndrome D018370 1 associated lipids
Neoplasms, Germ Cell and Embryonal D009373 4 associated lipids
Bronchopulmonary Sequestration D001998 3 associated lipids
Colitis, Ischemic D017091 3 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Alabaster VA et al. UK-74,505, a novel and selective PAF antagonist, exhibits potent and long lasting activity in vivo. 1991 Agents Actions Suppl. pmid:1793066
Heuer HO The effects of hetrazepine PAF antagonists in preclinical models of asthma. 1991 Agents Actions Suppl. pmid:1793067
Mazzoni L et al. Changes in airway sensitivity to histamine are not necessarily paralleled by changed sensitivity to acetylcholine. 1991 Agents Actions Suppl. pmid:1793069
Mest HJ et al. Effect of BN 52256 and other mediator antagonists on ouabain-induced ventricular fibrillation in sensitized guinea-pigs and on ischemia-induced fibrillation in rats. 1992 Agents Actions Suppl. pmid:1632298
Koltai M and Braquet PG Involvement of PAF in atherogenesis. Brief review. 1992 Agents Actions Suppl. pmid:1632308
McMillan RM and Carter GW Design and development of drugs. 1991 Agents Actions Suppl. pmid:1664186
Kurosawa M Effect of platelet activating factor on histamine release from rat mast cells. 1987 Agents Actions Suppl. pmid:2445185
Page CP and Spina D The therapeutic relevance of PAF antagonists. 1989 Agents Actions Suppl. pmid:2683635
Rink TJ Stimulus-response coupling mechanisms in human platelets. 1986 Agents Actions Suppl. pmid:3028101
Baroggi N et al. Changes in cytosolic free calcium induced by platelet-activating factor in rabbit platelets: specific inhibition by BN 52021 and structurally related compounds. 1986 Agents Actions Suppl. pmid:3028108
Muirhead EE Vasodepressor lipid of the renomedullary interstitial cells of the renal papilla is a prohormone activated by the liver. 1987 Agents Actions Suppl. pmid:3324720
Etienne A et al. Antithrombotic activity of BN 50341, a structurally new compound with anticalcic and PAF-antagonistic properties. 1986 Agents Actions Suppl. pmid:3468781
Guinot P et al. Effects of BN 52063 on PAF-acether induced weal and flare in man. 1987 Agents Actions Suppl. pmid:3479000
Lang M et al. Effects of the PAF-antagonist CV-3988 on PAF-induced changes in mucus secretion and in respiratory and circulatory variables in ferrets. 1987 Agents Actions Suppl. pmid:3479001
Codde JP et al. Effects of altered prostanoid and lyso-PAF synthesis by marine oil diets on blood pressure of salt loaded spontaneously hypertensive rats. 1987 Agents Actions Suppl. pmid:3481207
Morley J et al. Pharmacological evaluation of prophylactic anti-asthma drugs by reference to the pathological sequelae of exposure to allergen or platelet activating factor. 1988 Agents Actions Suppl. pmid:3262989
Subissi A and Criscuoli M Effects of LG 30435 on different platelet activating factor-induced responses. 1988 Agents Actions Suppl. pmid:3262990
Heuer H and Casals-Stenzel J Effect of the PAF-antagonist WEB 2086 on anaphylactic lung reaction: comparison of inhalative and intravenous challenge. 1988 Agents Actions Suppl. pmid:3262991
Anderson GP and Fennessy MR Lipoxygenase metabolites as mediators of platelet activating factor-induced increased airways responsiveness to histamine in the guinea-pig. 1988 Agents Actions Suppl. pmid:3140616
Stenzel H et al. Effect of the PAF-antagonist SRI 63-441 on the allergic reaction in awake dogs with natural asthma. 1987 Agents Actions Suppl. pmid:2823582
O'Flaherty JT and Wykle RL Metabolic origin and fate of platelet-activating factor. 1987 Agents Actions Suppl. pmid:2823583
Bertrand C et al. Selective implication of thromboxane A2 and PAF-acether in two guinea pig anaphylactic models. 1990 Agents Actions Suppl. pmid:2080755
Tsunoda H et al. Effects of a novel PAF antagonist, E6123, on PAF-induced biological responses. 1990 Agents Actions Suppl. pmid:2080757
Sakuma Y et al. Effects of a novel PAF antagonist, E6123, on passive anaphylaxis. 1990 Agents Actions Suppl. pmid:2080758
König W et al. On the biological role of lipid chemotactic factors. 1983 Agents Actions Suppl. pmid:6404145
Parnham MJ et al. Regulation of the oxidative burst of macrophages by lipid mediators. 1984 Agents Actions Suppl. pmid:6433680
Vargaftig BB Phospholipids, particularly platelet-activating factor (PAF-acether), in experimental bronchoconstriction. 1983 Agents Actions Suppl. pmid:6575594
Page CP et al. PAF-acether: a putative mediator of asthma and inflammation. 1983 Agents Actions Suppl. pmid:6575595
Hartung HP et al. Stimulation of the oxidative burst in macrophages with platelet activating factor (PAF-acether). 1982 Agents Actions Suppl. pmid:6960648
Madi S et al. Allergen-induced bronchospasm in passively sensitized guinea pigs: influence of new substances in comparison to reference compounds. 1991 Agents Actions pmid:2058463
Braquet P and Esanu A New trends in PAF antagonist research: a new series of potent hetrapazine-derived PAF antagonists. 1991 Agents Actions pmid:2058466
Northover AM Modification by some antagonists of the shape changes of venous endothelial cells in response to inflammatory agents in vitro. 1990 Agents Actions pmid:2111079
McLeod J et al. Effect of 12-O-tetradecanoylphorbol-13-acetate (TPA) on substance P-induced histamine release from rat peritoneal mast cells. 1990 Agents Actions pmid:1695435
Desai S and Barton R Role of platelet activating factor in the pathogenesis of active and passive models of experimental allergic encephalomyelitis in the rat. 1990 Agents Actions pmid:2285021
Adolfs MJ et al. PAF-acether modifies human peritoneal macrophage cAMP levels in a biphasic fashion. 1989 Agents Actions pmid:2540635
Trebien HA and Calixto JB Pharmacological evaluation of rat paw oedema induced by Bothrops jararaca venom. 1989 Agents Actions pmid:2660497
Bekemeier H and Sänze JU Vasodepression ex vivo after administration of inflammatory mediators in vivo in the rat. 1989 Agents Actions pmid:2476918
Jouquey S et al. Comparison of the effects of the ace inhibitors trandolapril and enalapril on phlogogen induced foot pad oedema in the rat. 1988 Agents Actions pmid:2459935
Sanchez Crespo M and Nieto ML Modulation of PAF biosynthesis in human polymorphonuclear leukocytes. The role of phorbol esters and protein kinases. 1989 Agents Actions pmid:2711927
Zijlstra FJ et al. The effects of PAF-acether and FMLP on eicosanoid production in guinea pig alveolar macrophages. 1989 Agents Actions pmid:2711928
Nijkamp FP et al. Role of platelet activating factor in the endotoxin induced tracheal hyperreactivity to histamine in the guinea pig. 1989 Agents Actions pmid:2711929
Oliver JL et al. Effect of PAF acether on oriented egg phosphatidylcholine multibilayers; interaction with cholesterol; comparison to lyso-PC and lyso-PAF. 1989 Agents Actions pmid:2711930
Howat DW et al. An investigation into the possible involvement of platelet activating factor in experimental allergic encephalomyelitis in rats. 1989 Agents Actions pmid:2801340
Appleby P and Bowen JG Cutaneous inflammatory disorders. 1990 Agents Actions pmid:2117335
Lundgren JD et al. Platelet activating factor and tracheobronchial respiratory glycoconjugate release in feline and human explants: involvement of the lipoxygenase pathway. 1990 Agents Actions pmid:2117336
Doyle SA et al. Further studies on the antinociceptive effects of delta 6-THC-7-oic acid. 1990 Agents Actions pmid:2178317
Nieminen MM et al. Body temperature modulates the effect of platelet-activating factor (PAF) on airways responsiveness in the rabbit. 1991 Agents Actions pmid:1862740
Jenei B et al. Hypotensive action of IgG preparations containing aggregates is suppressed by PAF-receptor antagonist BN 52021 and by gadolinium chloride (an agent blocking Kupffer cell function). 1991 Agents Actions pmid:1862750
Kantar A et al. Effect of PAF on erythrocyte membrane heterogeneity: a fluorescence study. 1991 Agents Actions pmid:1862752
Swingle KF and Reiter MJ Inhibition of Paf-acether-induced edema of the rat's paw. 1986 Agents Actions pmid:2875631
Flower RJ Background and discovery of lipocortins. 1986 Agents Actions pmid:2938452
Adnot S et al. Antagonists of PAF-acether do not suppress thrombin-induced aggregation of ADP-deprived and aspirin-treated human platelets. 1987 Agents Actions pmid:3115070
Montrucchio G et al. The pattern of cardiovascular alterations induced by infusion of platelet-activating factor in rabbit is modified by pretreatment with H1-H2 receptor antagonists but not by cyclooxygenase inhibition. 1987 Agents Actions pmid:3115072
Carlson RP et al. Pharmacologic modulation of PAF-induced mortality in mice. 1987 Agents Actions pmid:3120513
Anderson GP et al. Increased airways responsiveness to histamine induced by platelet activating factor in the guinea-pig: possible role of lipoxygenase metabolites. 1988 Agents Actions pmid:3136622
Cahill M et al. Effect of des arginine9-bradykinin and other bradykinin fragments on the synthesis of prostacyclin and the binding of bradykinin by vascular cells in culture. 1988 Agents Actions pmid:3051930
Cunha FQ et al. Failure of PAF-acether to induce in vivo neutrophil migration. 1988 Agents Actions pmid:3055873
Touvay C et al. Inhibition of antigen-induced lung anaphylaxis in the guinea-pig by BN 52021 a new specific paf-acether receptor antagonist isolated from Ginkgo biloba. 1986 Agents Actions pmid:3754380
Taira M et al. Lack of involvement of leukotriene and platelet activating factor in passive cutaneous anaphylaxis in rats. 1988 Agents Actions pmid:3407549
Etienne A et al. In vivo inhibition of plasma protein leakage and Salmonella enteritidis-induced mortality in the rat by a specific paf-acether antagonist: BN 52021. 1986 Agents Actions pmid:3515870
Mastacchi R et al. Interaction of a new low molecular weight heparin (OP/LMWH) with human platelets. 1986 Agents Actions pmid:3518359
Kusner EJ et al. Pharmacologic analysis of 1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine-induced increases in cutaneous vascular permeability in the rat. 1987 Agents Actions pmid:3577957
Pettipher ER et al. PAF-acether in chronic arthritis. 1987 Agents Actions pmid:3630862
Archer CB et al. Actions of disodium cromoglycate (DSCG) on human skin responses to histamine, codeine and Paf-acether. 1985 Agents Actions pmid:3923788
Parente L et al. The effect of glucocorticoids on lyso-PAF formation in vitro and in vivo. 1986 Agents Actions pmid:3962774
Tarayre JP et al. Inflammatory action of PAF-acether in the rat pleural cavity. 1986 Agents Actions pmid:3962789
Pirotzky E et al. Vascular permeability induced by Paf-acether (platelet-activating factor) in the isolated perfused rat kidney. 1985 Agents Actions pmid:4003192
Page CP et al. Platelet activating factor (Paf-acether) may account for late-onset reactions to allergen inhalation. 1985 Agents Actions pmid:4003195
Page CP et al. Suppression of Paf-acether responses: an anti-inflammatory effect of anti-asthma drugs. 1985 Agents Actions pmid:4003196
Spicer BA et al. An investigation of the involvement of platelet activating factor in the non-histamine immediate hypersensitivity reaction in the rat peritoneal cavity. 1985 Agents Actions pmid:4003197
Boughton-Smith NK et al. Actions of nitric oxide on the acute gastrointestinal damage induced by PAF in the rat. 1992 Agents Actions pmid:1279960
Northover AM In vitro effects of PAF on venous endothelial cell actin disposition. 1992 Agents Actions pmid:1509977
Okamoto H et al. Suppression of the Arthus reaction by Y-24180, a potent and specific antagonist of platelet-activating factor. 1992 Agents Actions pmid:1388318
Rachmilewitz D et al. Cytokines and platelet-activating factor in human inflamed colonic mucosa. 1992 Agents Actions pmid:1359744
Ogunbiyi PO and Eyre P Pharmacological studies of pulmonary anaphylaxis in vitro: a review. 1985 Agents Actions pmid:2420161
Benveniste J Platelet-activating factor (PAF-acether): present status. 1981 Agents Actions pmid:6176101
Northover AM and Northover BJ Lectin-induced increase in microvascular permeability to colloidal carbon in vitro may involve protein kinase C activation. 1994 Agents Actions pmid:7942320
Tubaro E et al. In vitro and in vivo impact of a new glycosphingolipid on neutrophils. 1994 Agents Actions pmid:7879694
Canale P et al. TCV-309, a novel platelet activating factor antagonist, inhibits leukocyte accumulation and protects against splanchnic artery occlusion shock. 1994 Agents Actions pmid:7879698
Glaser KB et al. Pharmacological characterization of WAY-121,520: a potent anti-inflammatory indomethacin-based inhibitor of 5-lipoxygenase (5-LO)/phospholipase A2 (PLA2). 1993 Agents Actions pmid:8273577
Kantar A et al. Effect of PAF on human lymphocyte membranes: a fluorescence study. 1993 Agents Actions pmid:8317302
Boonen GJ et al. Activation of neutrophil migration by dioctanoyl-sn-glycerol and fMet-Leu-Phe is controlled by different pathways. 1993 Agents Actions pmid:8317308
Murphy G Report of the 14th meeting of the British Inflammation Research Association. Topic: cellular and molecular aspects of inflammatory bowel disease. 1993 Agents Actions pmid:8480529
Sakamoto T et al. Effect of beta 2-adrenoceptor agonists against platelet-activating factor-induced airway microvascular leakage and bronchoconstriction in the guinea pig. 1993 Agents Actions pmid:7908496
Perret BA et al. Binding of bovine factor VIII-coated colloidal gold particles to receptors on platelet membranes. 1981 Agents Actions pmid:6803540
Denburg JA et al. Platelet activating factor: regulation by mast cells and aspirin. 1984 Agents Actions pmid:6711391
Lecrubier C et al. Study of platelet aggregation induced by platelet activating factor (PAF) after administration of ticlopidine or aspirin. 1983 Agents Actions pmid:6858789
Jouvin-Marche E et al. Platelet-activating factor (PAF-acether), an activator of neutrophil functions. 1982 Agents Actions pmid:6299078
Caillard CG et al. Hypotensive activity of PAF-acether in rats. 1982 Agents Actions pmid:6299079
Vargaftig BB Platelet-activating factor (PAF-acether) 1982 Agents Actions pmid:7164939
Bette P and Bienvenue A Exchange of a spin-labeled analog of PAF-acether between micelles, serum albumin and model membranes. 1982 Agents Actions pmid:7164940
Lartigue-Mattei C et al. Pharmacokinetic study of PAF-acether. Preliminary results after the intravenous administration of a 3H-labelled product to the rabbit. 1982 Agents Actions pmid:7164941
Lefort J et al. Pharmacological properties of PAF-acether in the guinea-pig: platelet-dependent and independent reactions. 1982 Agents Actions pmid:7164948
Vargaftig BB et al. Platelet-tissue interaction: role of platelet-activating factor (PAF-acether). 1980 Agents Actions pmid:7270336
Heller R et al. S35b, a new phenylsulfonylfuroxan compound, inhibits thrombin-induced synthesis of platelet-activating factor and prostacyclin in human endothelial cells. 1993 Agents Actions pmid:7517616
Izzo AA et al. Platelet activating factor potentiates rat paw oedema induced by different phlogogen agents. 1994 Agents Actions pmid:7524288
Lartigue-Mattei C et al. Pharmacokinetic study of 3H-labelled PAF-acether II. Comparison with 3H-labelled lyso-PAF-acether after intravenous administration in the rabbit and protein binding. 1984 Agents Actions pmid:6532184
Czarnetzki BM and Benveniste J Effect of synthetic PAF-acether on human neutrophil function. 1981 Agents Actions pmid:7041568
Camussi G et al. Neutropenia induced by platelet-activating factor (PAF-acether) released from neutrophils: the inhibitory effect of prostacyclin (PGI2). 1981 Agents Actions pmid:7041569
de Bernardis E et al. Protective effects of papaverine salicylate in mouse ear dermatitis and PAF-induced rat paw oedema. 1994 Agents Actions pmid:7847181